Patient Characteristics | Total Cohort (NÂ =Â 35) | Pazopanib-induced HTN (NÂ =Â 20) | No Pazopanib-induced HTN (NÂ =Â 15) | P-value |
---|---|---|---|---|
Male Gender | 20 (57) | 12 (60) | 8 (53) | 0.697 |
Age, years | 61.9 ± 9.1 | 62.8 ± 10.4 | 60.7 ± 7.2 | 0.479 |
Pazopanib Therapy | ||||
Initial dose 800Â mg QD | 32 (91) | 18 (90) | 14 (93) | 1 |
Initial dose 400Â mg QD | 3 (9) | 2 (10) | 1 (7) | 1 |
Dose reduction | 6 (17) | 6 (30) | 0 (0) | 0.027 |
Tumor Histology | ||||
Clear cell | 28 (80) | 17 (85) | 11 (73) | 0.693 |
Papillary | 4 (11) | 2 (10) | 2 (13) | 0.712 |
Poorly differentiated | 3 (9) | 1 (5) | 2 (13) | 0.849 |
ECOG PS | ||||
0 | 8 (23) | 7 (35) | 1 (7) | 0.101 |
1 | 19 (54) | 10 (50) | 9 (60) | 0.734 |
≥2 | 8 (23) | 3 (15) | 5 (33) | 0.246 |
Nephrectomy | 22 (63) | 12 (60) | 10 (67) | 0.687 |
Heart Failure | 2 (6) | 1 (5) | 1 (7) | 1 |
LV Dysfunction | 7 (20) | 2 (10) | 5 (33) | 0.112 |
Diabetes Mellitus | 15 (43) | 9 (45) | 6 (40) | 0.775 |
Hypertension | 21 (60) | 14 (70) | 7 (47) | 0.173 |
Systolic BP, mm Hg | 126.9 ± 10.8 | 130.5 ± 10.9 | 121.7 ± 8.2 | 0.010 |
Diastolic BP, mm Hg | 72.3 ± 7.4 | 74.4 ± 8.5 | 69.7 ± 4.4 | 0.045 |
Dyslipidemia | 17 (49) | 10 (50) | 7 (47) | 0.851 |
GFRÂ <Â 60Â mL/min/1.73Â m2 | 20 (57) | 11 (55) | 9 (60) | 0.767 |
CAD/PAD | 5 (14) | 2 (10) | 3 (20) | 0.631 |
CVA/TIA | 3 (9) | 3 (15) | 0 (0) | 0.244 |
Thromboembolism | 7 (20) | 3 (15) | 4 (27) | 0.430 |
Smoker | 21 (60) | 14 (70) | 7 (47) | 0.297 |
BMI, kg/m2 | 29.4 ± 8.7 | 28.8 ± 6.8 | 30.2 ± 11.0 | 0.680 |
ACEIs/ARBs | 14 (40) | 11 (55) | 3 (20) | 0.046 |
Beta Blockers | 11 (31) | 5 (25) | 6 (40) | 0.467 |
Diuretics | 7 (20) | 5 (25) | 2 (13) | 0.672 |
CCBs | 9 (26) | 7 (35) | 2 (13) | 0.244 |
Statin | 13 (37) | 8 (40) | 5 (33) | 0.737 |
Deceased | 15 (43) | 9 (45) | 6 (40) | 0.767 |
Follow-up time, months | 10.0 [3.1-19.4] | 11.7 [4.2-20.9] | 6.9 [2.1-17.7] | 0.257 |